| Combination of | |
|---|---|
| Atenolol | Beta blocker |
| Chlortalidone | Thiazide diuretic |
| Clinical data | |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| ChemSpider | |
| (verify) | |
Co-tenidone (BAN) is a non-proprietary name used to denote a combination of atenolol and chlortalidone. Co-tenidone is used in the treatment of hypertension. The use of β-blockers in hypertension was downgraded in June 2006 in the United Kingdom to fourth-line because they perform less well than other drugs, and because atenolol, the most frequently used β-blocker, at usual doses carries an unacceptable risk of provoking type 2 diabetes.
Formulation
Two strengths of co-tenidone are currently available in the UK:
- 50 mg atenolol and 12.5 mg chlortalidone, BAN of Co-tenidone 50/12.5
- 100 mg atenolol and 25 mg chlortalidone, BAN of Co-tenidone 100/25
References
- British National Formulary 54, September 2007
Footnotes
- Ladva S (2006-06-28). "NICE and BHS launch updated hypertension guideline". National Institute for Health and Clinical Excellence.
| Sympatholytic (and closely related) antihypertensives (C02) | |||||
|---|---|---|---|---|---|
| Sympatholytics (antagonize α-adrenergic vasoconstriction) | |||||
| Other antagonists |
| ||||
| |||||